Crinetics Pharmaceuticals focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. All of our drug candidates are new chemical entities resulting from in-house drug discovery.
We take a patient-focused approach to our work, which means our scientists begin the drug discovery process by talking to patients and their healthcare providers. Our goal is to understand what the needs are and how our work can achieve more effective disease control while helping improve patients’ daily lives.
PATIENT INSIGHTS PROGRAM
Share Your Opinions
The Crinetics Patient Insights Program (PIP) is a forum that gives patients an opportunity to contribute to drug development through important market research. If you are living with carcinoid syndrome stemming from neuroendocrine tumors (NETs), we’d love to hear from you. As a participant, you would play a key role by:
Sharing your perspectives via online surveys, virtual calls, and focus groups
Taking part in discussions around patient needs, current treatments, and your daily life
Contributing to the vital dialog we are committed to continue with people like you
Patients in the PIP are contacted 4-6 times per year to provide opinions and insights regarding their medical condition. PIP members are compensated a fair market value for their time.
Learn more about the Patient Insights Program at Crinetics and sign up here.
PATIENT LEADERSHIP COUNCIL
Your Voice Matters
The Patient Leadership Council (PLC) for carcinoid syndrome due to NETs is also a key way Crinetics practices a patient-focused approach to drug development. This forum gives patients a seat at the table, with opportunities to share their perspectives and first-hand experiences on important topics relevant to their condition, such as:
The journey to diagnosis
Unmet needs regarding NETs
Clinical trial experiences and feedback
Those chosen for the PLC serve for 12 months and attend a monthly video conference call. Members are compensated a fair market value for their time.
Email firstname.lastname@example.org to learn more.
CRN00808-11: OPEN-LABEL TRIAL IN PATIENTS WITH CARCINOID SYNDROME
Oral, Once-Daily Therapy
This study is a Phase 2 clinical research study exploring an investigational drug, paltusotine. The goal is to understand how the study drug affects symptoms of Carcinoid Syndrome. The study will consist of an 8-week treatment period followed by a 50-week extension phase for eligible patients.
“Investigational” means that the study drug has not been approved by regulatory authorities like the US Food and Drug Administration (FDA) or European Medicines Agency (EMA) and can only be used for research purposes.
Who can participate?
Naïve or treated with octreotide or lanreotide
BM and flushing criteria
Positive SSTR expression
Grade 1 or 2 NET
What to expect if I join the study
Receive health assessments to see if you qualify for the study
Take the study drug once a day by mouth for the duration of your participation
Attend study clinic visits to receive health assessments
Check in with the study staff 30 days after you stop taking the study drug to check your health
Click here to learn more about this study